Aurobindo Pharma receives USFDA Approval for Paricalcitol Capsules

18 Jan 2016 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Paricalcitol Capsules, 1 mcg, 2 mcg, and 4 mcg. This product is expected to be launched in Q1 FY16-17. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Zemplar capsules 1 mcg, 2 mcg and 4 mcg of ABBVIE.

Paricalcitol Capsules is used for the prevention and treatment of high levels of parathyroid hormone in certain patients with chronic kidney disease. The approved product has an estimated market size of $38 million for the twelve months ending November 2015 according to IMS.

This is the 58th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. The pharma major now has a total of 231 ANDA approvals (200 Final approvals including 10 from Aurolife Pharma LLC and 31 Tentative approvals) from USFDA.


Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×